The short version of AOD9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-27. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
PVA glues create plastic joints, which will creep over time if heavy loads are applied to them. Hide glue is supplied in many different gram strengths, each suited to specific applications. Instrument and cabinet builders will use a range from 120 to 200 gram strength. Some hide glues are sold without the gram strength specified. Experienced users avoid this glue as the glue may be too weak or strong for the expected application.
=== Infrared radiofluorescence === Infrared radiofluorescence (sometimes spelt radio-fluorescence) is a dating technique involving the infrared (~ 880 nm) luminescence signal of orthoclase from exposure to ionizing radiation. It can reveal the last time of daylight exposure of sediments, e.g., a layer of sand exposed to light before deposition.
== Pharmacology == Like ibogaine, it has seems to have similar pharmacology. It has effects on KOR, NMDAR, nAChR and serotonin sites. It also inhibits acetylcholinesterase and butyrylcholinesterase. Ibogamine persistently reduced the self-administration of cocaine and morphine in rats. The same study found that ibogamine (40 mg/kg) and coronaridine (40 mg/kg) did not produce "any tremor effects in rats that differ significantly from saline control". While the related alkaloids ibogaine (20–40 mg/kg), harmaline (10–40 mg/kg) and desethylcoronaridine (10–40 mg/kg) were "obviously tremorgenic".
Sources: en.wikipedia.org
Joy Stevenson Heeley, lately Revenue Officer, Board of Inland Revenue. Thomas William Heler, Member, Staffordshire Parish Councils Association. For services to Local Government. Mabel Evelyn Jeanette Henderson. For services to the Guide Association in Shetland. Joan Elizabeth Hetherington. For public service. Major John Wilfred Barratt Hext, , Voluntary Observer, Meteorological Office, Cumbria. Sheila Jean Hibbert. For services to Young People in London. Herbert Vincent Higgins. For services to the Retired and Senior Volunteer Programme. Eileen Jeanne Hodder. For services to the community in Richmond upon Thames, Surrey. Eileen Hodgkinson. For political and public service Marjone Hodgson. For services to the community in York. Mavis Ruth Hogg. For services to Lawn Tennis. Olive Holden. For services to the Cancer Relief Macmillan Fund in Perthshire. David George Holland, Senior Road Safety Officer, Durham County Council. For services to Road Safety. John Kenneth Hollis. For charitable services in Kent. Thomas Holmes, lately Assistant Director, Environmental Services, Trafford Metropolitan Borough Council. For services to the Environment. Albert Joseph Thomas Honey. For services to Animal Welfare in Oxfordshire. James William Hopkins, lately Manager, District Office, East Midlands Electricity plc. For services to the Electricity Industry. Robert Hopper, Road Worker, Highways Division, Northumberland Contracting. For services to Highways Maintenance. Olive Mary Hopton. For services to the community in Irlam, Manchester. Beve Hornsby. For services to People with Dyslexia.
According to provisions of the Government of India Act 1935, a bicameral legislature of Assam province came into existence in 1937. After the Government of India Act 1935 was passed, it paved the way for the formation of Assam Legislative Assembly, and became a bicameral legislature. The strength of the House was 108, where all the members were elected. The Legislative Council (Upper House) was not less than 21 and not more than 22 members. The first sitting of its lower house, the Assam Legislative Assembly, took place on 7 April 1937 in the Assembly Chamber at Shillong. Shillong was the capital of the composite State of Assam. It had a strength of 108 members. However, the strength of the Assembly was reduced to 71 after the partition of India. After Indian independence, the Assam Legislative Council was abolished in 1952 and the Assam Legislative Assembly became unicameral. The reconstituted assembly had 108 members with 31 seats reserved for Scheduled Tribes and Scheduled Castes. In the years that followed, Assam was truncated to several smaller states. And over the years, with the changing geographical boundaries and increase in population, the strength of members has changed from 108 in 1952–57 to 114 in 1967-72 (the third Assembly) and by 1972-78 (the fifth Assembly) it had a strength of 126 members.
West Yorkshire contains 22 constituencies of the Parliament of the United Kingdom, and parts of the two constituencies of Selby and Weatherby and Easingwold. As of the 2024 United Kingdom general election, 19 of the constituencies are held by Members of Parliament from the Labour Party, two by members of the Conservative Party, and one by an Independent politician.
A single-molecule electrically operated motor made from a single molecule of n-butyl methyl sulfide (C5H12S) has been reported. The molecule is adsorbed onto a copper (111) single-crystal piece by chemisorption.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.